3D biopsies to better understand brain tumors

Researchers at the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) obtained a highly accurate recreation of human glioblastoma’s features using a novel 3D microscopy analysis. The study, published in the journal Acta Neuropathologica Communications, provides new information to help with the diagnose, by finding therapeutical targets and designing immunotherapeutical strategies. This new…

Details

Narayanan and Liotta testing therapeutic efficacy of potential COVID-19 treatments

Aarthi Narayanan, Associate Professor, and Lance Liotta, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), are conducting three studies to assess the therapeutic efficacy of candidate interventions for COVID-19 in mouse models. For the first study, the researchers hope to determine the survival advantage conferred by a therapeutic. For this study, the researchers are…

Details

Mayo Clinic researchers develop test to measure effect of breast cancer gene variants

ROCHESTER, Minn. ? Researchers at Mayo Clinic have combined results from a functional test measuring the effect of inherited variants in the BRCA2 breast and ovarian cancer gene with clinical information from women who received genetic testing to determine the clinical importance of many BRCA2 variants of uncertain significance (VUS). The findings were published today…

Details

Super-sensitive cancer blood test earns “Top 10” award from clinical research forum

Cancer biologists at Weill Cornell Medicine have been awarded a 2021 Top 10 Clinical Research Achievement Award from the Clinical Research Forum for their study last year describing a highly sensitive blood test for monitoring cancer progression and relapse. The findings, entitled “Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring,” were published June 1…

Details

New review compiles immunogenicity data on leading SARS-CoV-2 vaccine candidates

In a new Review, P.J. Klasse and colleagues present an extensive overview of the immunogenicity profiles of several leading SARS-CoV-2 vaccine candidates, including several developed under the auspices of the U.S. Government’s “Operation Warp Speed” program, as well as leading candidates from China and Russia. Since the paper was submitted, two of these vaccines –…

Details

The Lancet: 3-month interval between first and second dose of Oxford COVID-19 vaccine results in higher vaccine efficacy than 6-week interval

Exploratory analyses including 17,178 participants find that higher vaccine efficacy is obtained with a longer interval between the first and second standard dose (81% for 3-month interval vs 55% for up to 6-week interval). In addition, a single dose of vaccine is highly efficacious in the first 3 months (76% efficacy from 22 days after…

Details